FIELD: medicine.
SUBSTANCE: injectable pharmaceutical composition includes a solution of 3-acylbuprenorphine or its pharmacologically acceptable salt in a biocompatible organic solvent, with this injectable pharmaceutical composition having a stable release profile that lasts for more than one week, when administered to a patient or animal. The acyl group is an alkylcarbonyl group, the alkyl portion of the alkylcarbonyl group is a linear / branched chain with 1-20 carbon atoms. The biocompatible organic solvent is N-methyl-2-pyrrolidone.
EFFECT: when administered to a patient or animal, the proposed injectable pharmaceutical composition has a stable release profile lasting for more than one week.
7 cl, 6 dwg, 7 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| EXTENDED-RELEASE INJECTION COMPOSITION OF NALTREXONE | 2019 |
|
RU2806817C2 |
| THIN-FLUID COMPOSITION FOR INJECTIONS CONTAINING BUPRENORPHINE | 2011 |
|
RU2607498C2 |
| COMPOSITIONS CONTAINING BUPRENORPHINE | 2011 |
|
RU2608912C2 |
| DELIVERED PHARMACEUTICAL COMPOSITIONS WITH CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS | 2005 |
|
RU2390355C2 |
| PROSTACYCLIN ANALOGUE PREPARATIONS | 2017 |
|
RU2757903C2 |
| CRYSTALLINE FORM OF MALEATE OF CONDENSED PYRIDINE DERIVATIVE AND METHODS FOR USE THEREOF | 2016 |
|
RU2712280C2 |
| ABIRATERONE PRODRUGS | 2020 |
|
RU2822219C2 |
| USE OF OPIOID RECEPTOR ANTAGONIST WITH K-ACTIVITY AND VORTIOXETINE FOR TREATMENT OF DEPRESSIVE DISORDER WITH MELANCHOLIC FEATURES | 2014 |
|
RU2679661C1 |
| MIXTURES AND COMPOSITIONS CONTAINING ALKYLAMMONIUM EDTA SALT | 2017 |
|
RU2775780C2 |
| LIQUID DRUG RESERVOIRS | 2005 |
|
RU2390331C2 |
